Drugs / Jintrolong
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01495468 | Mar 2007 → Jan 2008 | pituitary deficiency | Changchun GeneScience Pharmaceutical Co., Ltd. | Completed | Met primary |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-08-21 | Changchun GeneScience Pharmaceutical Co., Ltd. | Jintrolong® New Dosage Form of Long-acting Somatropin Injection Approved genscigroup.com ↗ |
| 2024-05-17 | Changchun GeneScience Pharmaceutical Co., Ltd. | Jintrolong® PEG-rhGH from GenSci highlighted at ECE 2024 genscigroup.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Jintrolong | “Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies.” PMID 28566441 ↗ May 2017 |
| Known as | PEG-rhGH | “We assessed the efficacy and safety of a weekly pegylated human growth hormone (PEG-rhGH) (Jintrolong) vs daily rhGH for children with growth hormone deficiency (GHD).” PMID 28566441 ↗ May 2017 |
| Modality | Protein / enzyme biologic | “Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies.” PMID 28566441 ↗ May 2017 |